title: Repair of rat gastric mucosa: effect of 16,16-dimethyl prostaglandin E2.
abstract: Prostaglandins protect the gastric mucosa against a variety of injurious agents and may accelerate the recovery of the gastric mucosa following damage. In previous studies prostaglandins were given prior to the injurious agent, so it was not possible to distinguish their potential effects on accelerating repair or reducing initial damage. We have investigated the effect of 16,16-dimethyl prostaglandin E2 (dmPGE2) on the repair of the gastric mucosa after injury induced by several injurious agents. dmPGE2 was given orally 15 min prior to aspirin or sodium salicylate, or 30 min after aspirin, sodium salicylate, or ethanol. dmPGE2 delivered prior to injury reduced the aspirin-induced fall in mucosal potential difference (PD), but had no effect on that induced by sodium salicylate. dmPGE2 administered after ASA injury significantly increased recovery of PD (P < 0.05), but did not alter the rate of recovery of PD with other damaging agents. Histological damage was decreased in rats treated with dmPGE2 after aspirin compared to aspirin-only-treated rats (P < 0.02). Exogenous dmPGE2 protects and restores gastric mucosal integrity after aspirin damage but has no effect on the repair of sodium salicylate and ethanol injured mucosa, suggesting that repair of the gastric mucosa after aspirin damage is enhanced by dmPGE2 due to its ability to prevent ongoing damage, rather than directly enhancing repair processes.
authors.affiliation: University of Melbourne, Department of Medicine, Australia.
authors.forename: G A
authors.initials: GA
authors.lastname: Cook
authors.forename: S L
authors.initials: SL
authors.lastname: Elliott
authors.forename: M V
authors.initials: MV
authors.lastname: Skeljo
authors.forename: A S
authors.initials: AS
authors.lastname: Giraud
authors.forename: N D
authors.initials: ND
authors.lastname: Yeomans
mesh_terms: D015064:16,16-Dimethylprostaglandin E2 / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects; D002492:Central Nervous System Depressants / Q000009:adverse effects; D004353:Drug Evaluation, Preclinical; D000431:Ethanol / Q000009:adverse effects; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D006863:Hydrogen-Ion Concentration; D008297:Male; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012980:Sodium Salicylate / Q000009:adverse effects; D013272:Stomach Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D002492:Central Nervous System Depressants; D000431:Ethanol; D015064:16,16-Dimethylprostaglandin E2; D001241:Aspirin; D012980:Sodium Salicylate